Citation: Nc. Wolff et Rl. Ilaria, Establishment of a murine model for therapy-treated chronic myelogenous leukemia using the tyrosine kinase inhibitor STI571, BLOOD, 98(9), 2001, pp. 2808-2816
Authors:
Roumiantsev, S
de Aos, IE
Varticovski, L
Ilaria, RL
Van Etten, RA
Citation: S. Roumiantsev et al., The Src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase, BLOOD, 97(1), 2001, pp. 4-13
Authors:
Silvany, RE
Eliazer, S
Wolff, NC
Ilaria, RL
Citation: Re. Silvany et al., Interference with the constitutive activation of ERK1 and ERK2 impairs EWS/FLI-1-dependent transformation, ONCOGENE, 19(39), 2000, pp. 4523-4530
Authors:
Tomasson, MH
Sternberg, DW
Williams, IR
Carroll, M
Cain, D
Aster, JC
Ilaria, RL
Van Etten, RA
Gilliland, DG
Citation: Mh. Tomasson et al., Fatal myeloproliferation, induced in mice by TEL/PDGF beta R expression, depends on PDGF beta R tyrosines 579/581, J CLIN INV, 105(4), 2000, pp. 423-432
Authors:
Spencer, JA
Eliazer, S
Ilaria, RL
Richardson, JA
Olson, EN
Citation: Ja. Spencer et al., Regulation of microtubule dynamics and myogenic differentiation by MURF, astriated muscle RING-finger protein, J CELL BIOL, 150(4), 2000, pp. 771-784
Authors:
Li, SG
Ilaria, RL
Million, RP
Daley, GQ
Van Etten, RA
Citation: Sg. Li et al., The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity, J EXP MED, 189(9), 1999, pp. 1399-1412